Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rubik Therapeutics
Cambridge, Massachusetts, United Stateslinkedin.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Preclinical
01
Overview
Rubik Therapeutics leverages computational biology and genome-wide screens to develop engineered cell therapies for solid tumors. The company’s approach focuses on highly selective tumor targets and immune suppression modulators. No clinical results are publicly available yet; the company appears to be in preclinical development
- Therapeutic areas
- Oncology
- Modalities
- Cell therapies (engineered cell therapies, likely including CAR-T or similar approaches)
- Industry
- Biotech
02
Partnerships
LG Chem Life Sciences Innovation Center (LabCentral Golden Ticket winner)Illumina Accelerator (investor/partner)
Beyond the preview
Go deeper on Rubik Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rubik Therapeutics.